Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

suvorexant

An orally bioavailable antagonist of the orexin receptors orexin receptor type 1 (OX1R) and orexin receptor type 2 (OX2R), that can be used for the treatment of insomnia. Upon oral administration, suvorexant targets and binds to the orexin receptors OX1R and OX2R. This blocks the binding of the neuropeptides orexin-A and orexin-B to OX1R and OX2R, and prevents wakefulness that results from orexin signaling.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
US brand name:Belsomra
Code name:MK-4305
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search